Drugs for the Treatment of Chronic Hand Eczema: Successes and Key Challenges [Corrigendum]

Dubin C, Del Duca E, Guttman-Yassky E. Ther Clin Risk Manag. 2020;16:1319– 1332. The authors have advised the drug, ARQ-252, was misnamed in the paper as roflumilast (which is called ARQ-151 and ARQ-154 by the manufacturer). The drug named ARQ-252 by the manufact...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Dubin C, Del Duca E, Guttman-Yassky E
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	afx5931 chronic hand eczema delgocitinib dupilumab gusacitinib roflumilast Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/e29c8d896dc34349a1aa8ece5789d99b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e29c8d896dc34349a1aa8ece5789d99b
record_format	dspace
spelling	oai:doaj.org-article:e29c8d896dc34349a1aa8ece5789d99b2021-12-02T16:28:15ZDrugs for the Treatment of Chronic Hand Eczema: Successes and Key Challenges [Corrigendum]1178-203Xhttps://doaj.org/article/e29c8d896dc34349a1aa8ece5789d99b2021-03-01T00:00:00Zhttps://www.dovepress.com/corrigendum-drugs-for-the-treatment-of-chronic-hand-eczema-successes-a-peer-reviewed-article-TCRMhttps://doaj.org/toc/1178-203XDubin C, Del Duca E, Guttman-Yassky E. Ther Clin Risk Manag. 2020;16:1319– 1332. The authors have advised the drug, ARQ-252, was misnamed in the paper as roflumilast (which is called ARQ-151 and ARQ-154 by the manufacturer). The drug named ARQ-252 by the manufacturer should instead be classified as a JAK1 inhibitor in the paper. On page 1320, CHE Treatment Paradigm section, 1st paragraph, “There are also ongoing studies with phosphodiesterase type 4 inhibitors (PDE4) and inhibitors of highly inflammatory chemokines CCL2 and CCL5 for the treatment of mild to moderate CHE. 1,35– 38” should read “There are also ongoing studies with topical JAK1 inhibitors and inhibitors of highly inflammatory chemokines CCL2 and CCL5 for the treatment of mild to moderate CHE. 1,35– 38”. On page 1322, Table 1, Agent and Target/Mechanism columns, “Roflumilast (ARQ-252)” should read “ARQ-252” and “PDE4” should read “JAK1”. On page 1323, before Roflumilast section, new section added for ARQ-252:ARQ-252Another topical JAK inhibitor is currently under investigation for the treatment of CHE. ARQ-252, a topical JAK1 inhibitor, is under clinical evaluation in a phase 1/2b randomized parallel assignment trial involving 223 patients with chronic hand eczema. 37,90 On page 1323, Roflumilast section now reads “Roflumilast is a high potency selective inhibitor of the receptor for PDE4, which functions by degrading cyclic adenosine monophosphate (cAMP). 89 Blocking the PDE-4 receptor allows cAMP to signal the transcription of immune function genes such as anti-inflammatory IL-10, while simultaneously reducing the production of inflammatory cytokines such as TNFα and IFN γ, which have been identified as possibly involved in CHE. 15,91-93 Roflumilast has been investigated as a topical therapeutic for AD, 89 and though there are no current trials, it remains a possible therapeutic option for CHE in the future. The authors apologize for this error.Read the original articleDubin CDel Duca EGuttman-Yassky EDove Medical Pressarticleafx5931chronic hand eczemadelgocitinibdupilumabgusacitinibroflumilastTherapeutics. PharmacologyRM1-950ENTherapeutics and Clinical Risk Management, Vol Volume 17, Pp 233-234 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	afx5931 chronic hand eczema delgocitinib dupilumab gusacitinib roflumilast Therapeutics. Pharmacology RM1-950
spellingShingle	afx5931 chronic hand eczema delgocitinib dupilumab gusacitinib roflumilast Therapeutics. Pharmacology RM1-950 Dubin C Del Duca E Guttman-Yassky E Drugs for the Treatment of Chronic Hand Eczema: Successes and Key Challenges [Corrigendum]
description	Dubin C, Del Duca E, Guttman-Yassky E. Ther Clin Risk Manag. 2020;16:1319– 1332. The authors have advised the drug, ARQ-252, was misnamed in the paper as roflumilast (which is called ARQ-151 and ARQ-154 by the manufacturer). The drug named ARQ-252 by the manufacturer should instead be classified as a JAK1 inhibitor in the paper. On page 1320, CHE Treatment Paradigm section, 1st paragraph, “There are also ongoing studies with phosphodiesterase type 4 inhibitors (PDE4) and inhibitors of highly inflammatory chemokines CCL2 and CCL5 for the treatment of mild to moderate CHE. 1,35– 38” should read “There are also ongoing studies with topical JAK1 inhibitors and inhibitors of highly inflammatory chemokines CCL2 and CCL5 for the treatment of mild to moderate CHE. 1,35– 38”. On page 1322, Table 1, Agent and Target/Mechanism columns, “Roflumilast (ARQ-252)” should read “ARQ-252” and “PDE4” should read “JAK1”. On page 1323, before Roflumilast section, new section added for ARQ-252:ARQ-252Another topical JAK inhibitor is currently under investigation for the treatment of CHE. ARQ-252, a topical JAK1 inhibitor, is under clinical evaluation in a phase 1/2b randomized parallel assignment trial involving 223 patients with chronic hand eczema. 37,90 On page 1323, Roflumilast section now reads “Roflumilast is a high potency selective inhibitor of the receptor for PDE4, which functions by degrading cyclic adenosine monophosphate (cAMP). 89 Blocking the PDE-4 receptor allows cAMP to signal the transcription of immune function genes such as anti-inflammatory IL-10, while simultaneously reducing the production of inflammatory cytokines such as TNFα and IFN γ, which have been identified as possibly involved in CHE. 15,91-93 Roflumilast has been investigated as a topical therapeutic for AD, 89 and though there are no current trials, it remains a possible therapeutic option for CHE in the future. The authors apologize for this error.Read the original article
format	article
author	Dubin C Del Duca E Guttman-Yassky E
author_facet	Dubin C Del Duca E Guttman-Yassky E
author_sort	Dubin C
title	Drugs for the Treatment of Chronic Hand Eczema: Successes and Key Challenges [Corrigendum]
title_short	Drugs for the Treatment of Chronic Hand Eczema: Successes and Key Challenges [Corrigendum]
title_full	Drugs for the Treatment of Chronic Hand Eczema: Successes and Key Challenges [Corrigendum]
title_fullStr	Drugs for the Treatment of Chronic Hand Eczema: Successes and Key Challenges [Corrigendum]
title_full_unstemmed	Drugs for the Treatment of Chronic Hand Eczema: Successes and Key Challenges [Corrigendum]
title_sort	drugs for the treatment of chronic hand eczema: successes and key challenges [corrigendum]
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/e29c8d896dc34349a1aa8ece5789d99b
work_keys_str_mv	AT dubinc drugsforthetreatmentofchronichandeczemasuccessesandkeychallengescorrigendum AT delducae drugsforthetreatmentofchronichandeczemasuccessesandkeychallengescorrigendum AT guttmanyasskye drugsforthetreatmentofchronichandeczemasuccessesandkeychallengescorrigendum
_version_	1718383965100834816

Drugs for the Treatment of Chronic Hand Eczema: Successes and Key Challenges [Corrigendum]

Ejemplares similares